The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.
AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.
The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
